FDA Approves Novo Nordisk's Norditropin for Treatment of Short Stature Associated with a Rare Genetic Disorder PRINCETON, N.J., June 1 -- Novo Nordisk today announced that Norditropin® ...

Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin ® (somatropin) in a phase 2 ...

PRINCETON, N.J., Sept. 21 -- Novo Nordisk today announced that Norditropin(R) (somatropin [rDNA origin] injection) received approval from the U.S. Food and Drug Administration (FDA) for the treatment ...

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved FlexPro PenMate, which is intended for patients who use Norditropin (somatropin [rDNA origin]) FlexPro 5mg, 10mg, and ...

To earn CME related to this news article, click here. January 7, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to warn of sudden death reports in pediatric ...

Feb. 24, 2005 — The U.S. Food and Drug Administration (FDA) approved in November and December 2004 revisions to safety labeling to advise healthcare professionals of the following changes: use of ...

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved a new 30mg/3.0mL strength of Norditropin (somatropin [rDNA origin] injection) FlexPro pen. Somatotropin binds to a ...

Eddie held up Bryan the Lion, a stuffed animal with its very own tiny plush injector pen and little blue stars stitched onto its fuzzy body. "The stars are where we do the shots," his dad said, ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Norditropin® FlexPro® is a dial-a-dose pen containing the active ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial. The Danish ...